NEE
33
-8
CAG
57
6
UNH
52
3
XYL
39
13
CHRW
14
4
GM
46
6
BSX
70
2
WU
22
6
YUM
52
3
ABBV
40
5
MSI
52
2
ADP
65
6
DOW
24
9
MO
36
6
TROW
39
5
ADM
33
3
PXD
44
4
BLK
46
5
GD
52
14
PSA
35
5
NEE
33
-8
CAG
57
6
UNH
52
3
XYL
39
13
CHRW
14
4
GM
46
6
BSX
70
2
WU
22
6
YUM
52
3
ABBV
40
5
MSI
52
2
ADP
65
6
DOW
24
9
MO
36
6
TROW
39
5
ADM
33
3
PXD
44
4
BLK
46
5
GD
52
14
PSA
35
5
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
48

SRPT
Sarepta Therapeutics

Last Price:
126.28
Seasonality Move:
5.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $933.01M
Cash Flow: $-218.88M
Price / Cash Flow: 0
Annual Sales: $7.65
Price / Book: 16.36

Profitability

EPS (TTM): -12.69000
Net Income (TTM): $-1.12B
Gross Margin: $793.02M
Return on Equity: -179.19%
Return on Assets: -36.22%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 27 years for SRPT is 85.00%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 48.38% of Gross Profit Margin.
  • The Research & Development expenses have been 94.01% of Revenue.
  • The Interest Expense is -7.57% of Operating Income.
  • The Net Earning history of SRPT is -75.40% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 13 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.73
Current Ratio: 4.63
Quick Ratio: 4.04

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 17.7

SRPT Technical Analysis vs Fundamental Analysis

Sell
48
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?